NVCR
NovoCure Ltd

7,403
Mkt Cap
$1.51B
Volume
2.22M
52W High
$34.13
52W Low
$10.87
PE Ratio
-8.63
NVCR Fundamentals
Price
$12.82
Prev Close
$13.48
Open
$13.48
50D MA
$13.07
Beta
1.26
Avg. Volume
1.54M
EPS (Annual)
-$1.56
P/B
4.31
Rev/Employee
$406,733.87
Loading...
Loading...
News
all
press releases
Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics
The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·6h ago
News Placeholder
More News
News Placeholder
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of +21.43% and +5.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8h ago
News Placeholder
Novocure Reports Third Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in some of the most...
Business Wire·10h ago
News Placeholder
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in...
Business Wire·15d ago
News Placeholder
NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer
NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.
Zacks·2mo ago
News Placeholder
NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·3mo ago
News Placeholder
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of +7.69% and +3.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·4mo ago
News Placeholder
What Makes NovoCure (NVCR) a New Buy Stock
Zacks·4mo ago
News Placeholder
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
Zacks·5mo ago

Latest NVCR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.